DOMINGO, 24 de julio (HealthDay News) — Para los pacientes que sufren de dolor en el pecho, añadir el nuevo fármaco anticoagulante Eliquis a la terapia antiplaquetaria podría resultar en sangrado grave, sin reducir el riesgo de ataque cardiaco ni accidente cerebrovascular (ACV), halla un estudio reciente. Más
- Therapeutic novelties in acute heart failure and practical perspectives 23/01/2025
- Blood circulating LncRNAs: SNHG5 and ZFAS1 as biomarkers reflecting cachexia incidence in chronic heart failure patients 23/01/2025
- The association between county-level social determinants of health and cardio-kidney-metabolic disease attributed all-cause mortality in the US: A cross sectional analysis 23/01/2025
- Exercise training in heart failure and other research 23/01/2025
- Association with Outcome of the Regurgitant-Volume Adjusted Right Ventricular Ejection Fraction in Secondary Tricuspid Regurgitation 23/01/2025
 |
 |
 |
 |
- La FDA afirma que muchos medicamentos para el resfriado no funcionan; hará cambios 26/12/2024
- La SEMG recomienda a los servicios de Salud «tener preparados planes» frente al aumento de la gripe y del virus sincitial respiratorio 26/12/2024
- Déficit financiero deteriora respuestas al cólera en Yemen 25/12/2024
- Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer 25/01/2025
- Scientists design peptides to enhance drug efficacy 24/01/2025
- VR subway experiment highlights role of sound in disrupting balance for people with inner ear disorder 24/01/2025
- Study unveils key immune cells found to boost cancer treatment success in acute myeloid leukemia 24/01/2025
- Sepsis, or death by lethal message 24/01/2025
 |
6 de enero de 2025
| Sitio presentado el 18 de mayo de 2010 |  |
Haga un comentario